CONTRACT FOR CARE · RIGHTS, CONSENT & GOVERNMENT POWER
Our Legal Case
A patient’s need for medicine should not become the pressure used to obtain a criminal admission. Examine compulsory disclosures, penalties for silence, coerced rights waivers, and the circumstances behind the signature.
Use this state record to trace the legal requirement, then compare it with the terms an office adds. The full work explains the constitutional case, consent analysis, evidence needed, and protections to demand.
Apply the constitutional and consent review to this record
- Government responsibility: Which law, binding rule, agency instruction, or public-provider policy requires the particular disclosure or consequence? Separate it from provider-added terms.
- Potential criminal admission: Identify the exact spoken answer, written history, certification, or explanation and the real criminal risk it creates.
- Penalty for silence: Record what happens if the patient invokes the privilege or refuses a rights waiver, including denial, discharge, or interruption of treatment.
- Consent and pressure: Preserve the circumstances of signing, severity of pain, accessible alternatives, and whether the patient could honestly accept the prospective obligations.
- Criminal-use protection: Identify legally sufficient immunity and limits on use of both the answer and evidence derived from it. A privacy assurance is a separate protection.
Read the precedents, evidence framework, clause review, and remedies and reform demands. The work develops a proposed constitutional challenge; applying it to a particular condition requires its facts and legal authority.
Alaska · Contract for Care
Alaska Contract for Care — State Requirements and Incorporated Guidance
Alaska’s physician prescribing rule incorporates named clinical guidance. A fair comparison must distinguish that incorporated framework from a clinic’s exact promises, deadlines, fees and consequences.
The important distinction
Do not assume either that every agreement clause is state-mandated or that agreements have no regulatory basis. 12 AAC 40.975 references FSMB’s April 2017 guidance and CDC’s March 2016 guidance. The FSMB document recommends written agreements for long-term opioid treatment, including responsibilities for both patient and clinician.
| Authority | What the reviewed source provides | Limits of the comparison |
|---|---|---|
| AS 08.64.363 | Seven-day limit for specified initial adult outpatient opioid prescriptions and prescriptions to minors. | Documented professional-judgment exceptions include chronic pain, cancer, palliative care and travel/logistical barriers; read the full statute. |
| 12 AAC 40.975 | History, treatment and monitoring documentation; specified PDMP checks; a 50-MME daily maximum for initial prescriptions under AS 08.64.363(a). | The initial-prescription provision is not a universal ceiling for every existing long-term patient. PDMP exemptions and the applicable schedule matter. |
| Incorporated FSMB April 2017 guidance | Informed consent, written agreements, periodic testing, coordinated prescribing/pharmacy use and stated refill policies. | Recommendations do not supply every clinic’s exact testing deadline, disclosure waiver, fee or disciplinary rule. The guidance also addresses clinician responsibilities and safe transition of care. |
| Incorporated CDC March 2016 guidance | Recommendation 5 advises avoiding increases to 90 MME or carefully justifying them; it is not an automatic universal 90-MME cutoff. | A clinic’s mandatory threshold or automatic taper must be identified as its implementation. The guidance cautions against dismissal based solely on PDMP/testing information. |
| Alaska Medicaid prior-authorization form | The posted opioid quantity-limit/extended-release form requires a pain contract for requests using that form; second-level documentation includes a current copy. | This is a payer process for those requests, not proof that every Alaska patient or every opioid prescription needs the same contract. |
Source and version
- Alaska State Medical Board statutes and regulations, revised September 21, 2026: AS 08.64.363 and 12 AAC 40.975.
- FSMB Guidelines for the Chronic Use of Opioid Analgesics, April 2017: agreement discussion and termination/transition guidance.
- CDC 2016 prescribing guideline.
- Alaska Medicaid opioid prior-authorization form, printed revision October 3, 2022; verify current payer requirements before use.
- Alaska PDMP use exemptions.
What still needs individual review
This baseline concerns the general physician authorities reviewed. APRN, dental, payer and federal/tribal rules may differ. The newer CDC 2022 guidance does not automatically replace the editions named in Alaska’s regulation. Institutional policy and current signed paperwork must be checked separately.
A service listing does not guarantee opioid prescribing, insurance acceptance, eligibility or an available appointment. Patients should discuss treatment changes with their treating clinician.
Evidence limits: A publicly linked document does not confirm current signed use. “Office-selected” identifies specific wording not located in the general physician authorities reviewed; it is not a finding of illegality, enforceability or clinical necessity. Payer, federal/tribal and profession-specific requirements need separate review. Research checked October 13, 2026 UTC / October 12 Central.
Alaska facility directory · State requirements and incorporated guidance · Evidence library · Method and coverage · Alaska Pain Atlas
Our Legal Case presents Seeds of Vice’s broader legal argument. Listing a practice or reviewing its document is not a court finding about that practice.